Axonyx’ Phenserine Could Be First Alzheimer’s Agent Targeting Beta-Amyloid Plaques To Reach FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III trials for the acetylcholinesterase inhibitor are expected to complete in December 2004. Beta-amyloid is a primary therapeutic target as companies race to develop disease-modifying therapies that go beyond the symptom relief provided by current drugs. Statins and NSAIDs are also being examined for their potential to alter the course of AD.